Emergent BioSolutions Inc.
EBS
Rank in Stocks
#14614
Emergent BioSolutions Inc. is a life sciences company dedicated to providing... Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
Share Price
$6.10
Last synced: 2026-11-09
Market Cap
$312.77M
Change (1 day)
0.66%
Change (1 year)
-43.93%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Emergent BioSolutions Inc. (EBS)
Category
Healthcare
Operating Margin for Emergent BioSolutions Inc. (EBS)
Operating Margin as of November 2026 TTM: -7.06%
According to Emergent BioSolutions Inc.'s latest financial reports, its current operating margin (TTM) is -7.06%. At the end of 2025 the company had an operating margin of 14.83%.
Operating Margin history for Emergent BioSolutions Inc. from 2001 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -7.06% | -147.61% |
| 2025 | 14.83% | -242.32% |
| 2024 | -10.42% | -84.95% |
| 2023 | -69.23% | 355.16% |
| 2022 | -15.21% | -179.01% |
| 2021 | 19.25% | -30.76% |
| 2020 | 27.80% | 169.38% |
| 2019 | 10.32% | -10.10% |
| 2018 | 11.48% | -48.19% |
| 2017 | 22.16% | 2.69% |
| 2016 | 21.58% | -25.38% |
| 2015 | 28.92% | 31.16% |
| 2014 | 22.05% | 61.07% |
| 2013 | 13.69% | 5.55% |
| 2012 | 12.97% | 10.48% |
| 2011 | 11.74% | -54.32% |
| 2010 | 25.70% | 50.29% |
| 2009 | 17.10% | 2.03% |
| 2008 | 16.76% | -7.35% |
| 2007 | 18.09% | -27.35% |
| 2006 | 24.90% | 52.48% |
| 2005 | 16.33% | -18.72% |
| 2004 | 20.09% | -79.91% |
| 2003 | 100.00% | 107.94% |
| 2002 | 48.09% | -6,111.25% |
| 2001 | -0.80% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -105.47% |
US
|
|
| -149.01% | -78.89% |
US
|
|
| 25.57% | -103.62% |
AU
|
|
| 31.23% | -104.42% |
BE
|
|
| 29.35% | -104.16% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Emergent BioSolutions Inc.'s operating margin
What is Emergent BioSolutions Inc.'s operating margin?
Emergent BioSolutions Inc.'s operating margin is -7.06%, as of Nov 2026.
What was Emergent BioSolutions Inc.'s operating margin in 2025?
In 2025, Emergent BioSolutions Inc.'s operating margin was 14.83%, compared with -10.42% in 2024.
How has Emergent BioSolutions Inc.'s operating margin changed since 2020?
From 2020 to 2025, Emergent BioSolutions Inc.'s operating margin was highest in 2020 (27.80%) and lowest in 2023 (-69.23%).
How does Emergent BioSolutions Inc.'s operating margin compare with similar companies?
Emergent BioSolutions Inc.'s operating margin (-7.06%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.